Free Trial
NASDAQ:MGTX

MeiraGTx Q3 2025 Earnings Results & Report

MeiraGTx logo
$9.89 +0.48 (+5.10%)
Closing price 04:00 PM Eastern
Extended Trading
$9.89 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MeiraGTx missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.62 versus the -$0.50 consensus estimate, while revenue of $0.41 million fell short of the $7.71 million estimate by $7.30 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
8:00 AM ET

MeiraGTx EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.50
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

MeiraGTx Revenue Results

Actual Revenue
$0.41 million
Expected Revenue
$7.71 million
Beat/Miss
Missed by -$7.30 million
YoY Revenue Growth
N/A

Upcoming Earnings

MeiraGTx's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

MeiraGTx Q3 2025 Earnings FAQ

MeiraGTx (NASDAQ:MGTX) reported earnings of -$0.62 per share for Q3 2025, missing the consensus estimate of -$0.50. The report was announced on Thursday, November 13, 2025.

MeiraGTx reported revenue of $0.41 million for Q3 2025, against a consensus estimate of $7.71 million.

MeiraGTx's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for MeiraGTx on the company's earnings history page.

MeiraGTx Earnings Headlines

MeiraGTx: The Data Held Up, The Valuation Didn't (Rating Downgrade)
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
MeiraGTx Holdings plc (MGTX)
Goldman Sachs Initiates MeiraGTx at Neutral With $16 Price Target
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX) (NASDAQ:MGTX) is a clinical-stage biotechnology company developing gene therapy and ribonucleic acid (RNA) medicines for diseases with significant unmet medical needs. Its research focuses primarily on the central nervous system, immune-mediated conditions and disorders affecting salivary gland function.

The company’s technology platforms are designed to deliver therapeutic genes or regulate gene expression in targeted tissues. Its investigational programs have included gene therapies for Parkinson’s disease and radiation-induced xerostomia, a condition involving chronic dry mouth after cancer treatment. MeiraGTx has also pursued additional programs in neurological and other serious diseases, although its pipeline and development priorities may change as clinical studies progress.

Founded in 2015, MeiraGTx has built research, development and manufacturing capabilities in the United States and the United Kingdom. The company is led by Alexandra Forbes, who co-founded MeiraGTx and serves as president and chief executive officer.

View MeiraGTx Profile